Biovitrum (STO:BVT) Biovitrum's CEO Martin Nicklasson will give a company presentation at the 27th Annual J.P. Morgan Healthcare Conference being held January 12-15, 2009, in San Francisco, USA.

The presentation is scheduled to take place on Wednesday January 14 at 4:00 p.m. (PST). A live webcast, as well as an archived, will be available via Biovitrums website at www.biovitrum.com. The presentation material will be available on www.biovitrum.com under the link presentations on the investor relations page.



For more information please contact: Biovitrum Göran Arvidson, CFO Phone: +46 8 697 23 68

About Biovitrum Biovitrum is a pharmaceutical company with operations in Sweden and in the UK. The company markets a range of specialist pharmaceuticals. Using its expertise and experience Biovitrum takes scientific innovation all the way to the market and to specialist indication patients with significant medical need. Research expertise and capabilities include development and production of biotechnology therapeutics, as well as small molecule discovery and development. With revenues of approximately SEK 1.3 billion and around 500 employees, Biovitrum is a significant international specialty pharmaceutical player. Biovitrum's share is listed on the OMX Nordic Exchange in Stockholm. For more information go to www.biovitrum.com

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.



LINK: http://hugin.info/134557/R/1281605/286620.pdf

Biovitrum

http://www.biovitrum.com

ISIN: SE0000872095

Stock Identifier: XOME.BVT

ABN Newswire
ABN Newswire Diese Seite wurde besucht:  (letzten 7 Tagen: 4) (letzten 30 Tagen: 18) (seit Veröffentlichung: 1821)